Sodium-glucose cotransporter 2 inhibitors (SGLT2i): their role in cardiometabolic risk management
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a novel category of oral antidiabetic drugs that suppress renal glucose reabsorption and increase renal glucose excretion, thus lowering plasma glucose levels. This unique mechanism of SGLT2i action is insulin independent, thus improving glycemi...
| Hoofdauteurs: | , , |
|---|---|
| Formaat: | Journal article |
| Gepubliceerd in: |
Bentham Science Publishers
2017
|